Septerna, Inc. Common Stock SEPN
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-13T02:10:09.964Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T22:04:44.615545206Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-13T02:10:09.009373+00:00
Septerna, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 31.37 | 295.0% | 29.6% | |||
| 25Δ | 34.66 | 230.2% | 21.6% | |||
| 30Δ | 37.03 | 184.7% | 15.9% | |||
| 35Δ | 48.15 | 202.1% | 23.1% | 38.68 | 152.8% | 11.8% |
| 40Δ | 45.05 | 163.9% | 15.7% | 39.92 | 128.2% | 8.8% |
| 45Δ | 43.32 | 147.6% | 11.9% | |||
| 50Δ | 42.02 | 139.6% | 9.5% | |||
| 55Δ | 40.86 | 117.6% | 6.7% | |||
| 60Δ | 39.95 | 121.1% | 5.8% | 42.04 | 50.7% | 1.9% |
| 65Δ | 39.04 | 118.9% | 4.7% | 42.52 | 52.2% | 1.6% |
| 70Δ | 37.62 | 143.9% | 4.6% | |||
| 75Δ | 36.37 | 146.9% | 3.7% | |||
| 80Δ | 33.98 | 182.7% | 3.5% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 31.37
- IV
- 295.0%
- B/E move
- 29.6%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 34.66
- IV
- 230.2%
- B/E move
- 21.6%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 37.03
- IV
- 184.7%
- B/E move
- 15.9%
35Δ
- Pseudo strike
- 48.15
- IV
- 202.1%
- B/E move
- 23.1%
- Pseudo strike
- 38.68
- IV
- 152.8%
- B/E move
- 11.8%
40Δ
- Pseudo strike
- 45.05
- IV
- 163.9%
- B/E move
- 15.7%
- Pseudo strike
- 39.92
- IV
- 128.2%
- B/E move
- 8.8%
45Δ
- Pseudo strike
- 43.32
- IV
- 147.6%
- B/E move
- 11.9%
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- 42.02
- IV
- 139.6%
- B/E move
- 9.5%
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 40.86
- IV
- 117.6%
- B/E move
- 6.7%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 39.95
- IV
- 121.1%
- B/E move
- 5.8%
- Pseudo strike
- 42.04
- IV
- 50.7%
- B/E move
- 1.9%
65Δ
- Pseudo strike
- 39.04
- IV
- 118.9%
- B/E move
- 4.7%
- Pseudo strike
- 42.52
- IV
- 52.2%
- B/E move
- 1.6%
70Δ
- Pseudo strike
- 37.62
- IV
- 143.9%
- B/E move
- 4.6%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 36.37
- IV
- 146.9%
- B/E move
- 3.7%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 33.98
- IV
- 182.7%
- B/E move
- 3.5%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 83.53% | |
| 83.85% | |
| 84.98% | |
| 83.07% | |
| 83.90% | |
| 85.41% | |
| 87.58% | |
| 85.50% | |
| 85.09% | |
| 86.62% |
Biotechnology
SGMT
Sagimet Biosciences Inc. (SGMT) is an innovative biotechnology company focused on developing breakthrough treatments for metabolic diseases, particularly non-alcoholic…
More →SION
Sionna Therapeutics, Inc. is an innovative biotechnology company focused on developing advanced therapies for neurodegenerative disorders, notably Alzheimer's and Parkinson's…
More →SLDB
Solid Biosciences Inc., a life sciences company, is dedicated to developing therapies for Duchenne muscular dystrophy (DMD) in the United States. The company is headquartered in…
More →SLN
Silence Therapeutics plc, a biotechnology company, is focused on the discovery and development of new ribonucleic acid (RNA) therapies in hematology, cardiovascular, and other…
More →SLS
SELLAS Life Sciences Group, Inc., an advanced-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for various indications of cancer in the…
More →SMMT
Description unavailable
More →